IL17A and metabolic dysfunction-associated steatotic liver disease: Recent investigations have unveiled that MASLD triggers a rise in circulating and liver-resident CXCR3+ Th17 cells through glycolysis induction, enhancing their capacity to produce IL-17A, IFN-γ, and TNF-α (134).